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Introduction
Narcolepsy is a sleep-wake disorder characterized by exces-
sive daytime sleepiness (EDS) with sudden onset and an ab-
normal transition from wakefulness into rapid eye movement 
(REM) sleep. Other typical features are cataplexy, hypnago-
gic hallucinations, sleep paralysis, and automatic behavior. 
The International Classification of Sleep Disorders defines two 
subtypes of this disorder: narcolepsy with and without cata-
plexy. It is currently thought that narcolepsy is attributable to 
autoimmune processes that trigger a specific cell loss in the 
lateral and posterior hypothalamus,1 but more rarely it can be 
of symptomatic origin (e.g., inherited disorders, tumors, or 
multiple sclerosis).2 Hypothalamic cells secrete hypocretin and 
are integrated into different CNS networks (i.e., the reticular 
activating system, and the olfactory and autonomic systems). 
Although sleep-wake dysfunction is the cardinal syndrome, 
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Background and PurposezzExcessive daytime sleepiness and sudden sleep attacks are the 
main features of narcolepsy, but rapid-eye-movement sleep behavior disorder (RBD), hyposmia, 
and depression can also occur. The latter symptoms are nonmotor features in idiopathic Parkin-
son’s disease (IPD). In the present study, IPD-proven diagnostic tools were tested to determine 
whether they are also applicable in the assessment of narcolepsy.
MethodszzThis was a case-control study comparing 15 patients with narcolepsy (PN) and 15 
control subjects (CS) using the Scales for Outcomes in Parkinson’s Autonomic Test (SCOPA-
AUT), Parkinson’s Disease Nonmotor Symptoms (PDNMS), University of Pennsylvania Smell 
Test, Farnsworth-Munsell 100 Hue test, Beck Depression Inventory, and the RBD screening 
questionnaire.
ResultszzBoth the PN and CS exhibited mild hyposmia and no deficits in visual tests. Frequent 
dysautonomia in all domains except sexuality was found for the PN. The total SCOPA-AUT 
score was higher for the PN (18.47±10.08, mean±SD) than for the CS (4.40±3.09), as was the 
PDNMS score (10.53±4.78 and 1.80±2.31, respectively). RBD was present in 87% of the PN 
and 0% of the CS. The PN were more depressed than the CS. The differences between the PN 
and CS for all of these variables were statistically significant (all p<0.05).
ConclusionszzThe results of this study provide evidence for the presence of dysautonomia and 
confirm the comorbidities of depression and RBD in narcolepsy patients. The spectrum, which 
is comparable to the nonmotor complex in IPD, suggests wide-ranging, clinically detectable 
dysfunction beyond the narcoleptic core syndrome. J Clin Neurol 2014;10(4):314-319
Key Wordszz autonomic failure, multisystem disorder, narcolepsy, Parkinson’s disease.
Open Access
cc  This is an Open Access article distributed under the terms of the Cre-
ative Commons Attribution Non-Commercial License (http://creative-
commons.org/licenses/by-nc/3.0) which permits unrestricted non-com-
mercial use, distribution, and reproduction in any medium, provided the ori-
ginal work is properly cited.
Klein G et al.
www.thejcn.com  315
other symptoms may also occur: REM sleep behavior disorder 
(RBD), hyposmia, depression, and obesity. Clinical observa-
tions suggest that several of the encountered symptoms can 
also be seen in patients suffering from idiopathic Parkinson’s 
disease (IPD). Interestingly, RBD and hyposmia are often pro-
posed as harbingers of IPD.3,4 We hypothesize that further com-
monalities exist between narcolepsy and IPD.
Using validated and well-introduced IPD evaluation ques-
tionnaires and clinical tests, an exploratory case-control study 
was conducted to determine whether other nonmotor symp-
toms that are routinely found in IPD also occur in patients 
with narcolepsy (PN). In particular, we explored whether PN 
exhibit autonomic dysfunction or sensory deficits. However, 
since it was not possible to directly compare PN with IPD pa-
tients, they were compared directly with age-matched healthy 
control subjects (CS), and the observed scores were post-hoc 
compared with those reported in the literature for IPD pa-
tients, while remaining mindful of the methodological limi-
tations of such an approach.
Methods
Patients
Fifteen consecutively seen PN were prospectively enrolled in 
this study and were compared with 15 volunteer CS who were 
matched for gender and age. Narcolepsy with or without cat-
aplexy was diagnosed using the International Classification 
of Sleep Disorders II criteria, and polysomnography and the 
multiple sleep latency test. Hypocretin concentration in the 
cerebrospinal fluid (CSF) was not assessed since hypocretin 
status is not required for a clinical diagnosis. The following 
PN exclusion criteria were applied: any Parkinsonian features, 
secondary narcolepsy, and any preexisting diseases with au-
tonomic dysfunction (e.g., gastrointestinal diseases) that could 
affect the results. The CS exclusion criteria were EDS of un-
known origin or cataplexy, as established by the Epworth 
Sleepiness Scale and the Modified Cataplexy Emotional Trig-
ger Questionnaire, respectively.
Methods
Autonomic dysfunction was evaluated using the Scales for 
Outcomes in Parkinson-Autonomic (SCOPA-AUT) and Parkin-
son’s Disease Nonmotor Symptoms scales (PDNMS), which 
are both self-completed questionnaires. The University of 
Pennsylvania Smell Identification Test (UPSIT) was used for 
olfactory testing. Visual performance was first evaluated us-
ing Snellen charts and the Ishihara color test; color discrimi-
nation was then tested using the Farnsworth-Munsell 100 Hue 
Test (FM-100). The methodological details are reported else-
where.5 RBD assessment was conducted using the RBD Screen-
ing Questionnaire (RBD-SQ), and emotional assessment was 
achieved with the short Beck Depression Inventory (BDI).
For statistical analyses, the Mann-Whitney U test was used 
for nonnormal endpoints (as assessed by a Shapiro-Wilk test) 
and ANOVA was used in cases of normality. All tests were 
two-tailed and the cutoff for statistical significance was set at 
p<0.05.
The primary outcomes were the following variables: total 
scores on the SCOPA-AUT, PDNMS, UPSIT, FM-100, RBD-
SQ, and BDI. These primary variables were adjusted for mul-
tiplicity. All analyses were conducted using the Statistical 
Analysis System (SAS) statistical software (v9.2, SAS Insti-
tute, Cary, NC, USA). The study was approved by the National 
Ethical Committee in Luxembourg. All enrolled subjects pro-
vided written informed consent to participate prior to the study.
Results
The demographic data were as follows: 10 males and 5 females 
for both the PN and the CS; age, 35.1±15.8 years for PN and 
35.2±15.7 years for CS; and body mass index, 27.5±6.5 kg/m2 
for PN and 24.4±4.3 kg/m2 for CS. Smoker status did not reach 
statistical significance (PN n=4, CS n=1). The clinical histo-
ry was determined, and a clinical examination and polysom-
nography were performed to exclude any other concomitant 
cause for EDS in PN and CS (polysomnography was not 
performed in the CS). One of the PN suffered from sleep ap-
nea syndrome, but was well controlled by continuous positive 
airway pressure treatment, as documented by polysomnogra-
phy. None of the PN or CS was suffering from any other causes 
of EDS, such as insufficient sleep syndrome, shift work, or 
effects of substances or medications.
At study entry, the duration of narcolepsy was 13.6±5.6 
years, as documented by the patient charts. Nine PN (four 
women) had cataplexy, while six PN (one woman) were with-
out. Thirteen of the 15 PN were receiving specific treatment at 
study entry: modafinil (n=9), γ-hydroxybutyrate (n=1), and 
methylphenidate (n=1). The overall duration of treatment was 
4.1±4.1 years.
Autonomic evaluation
All autonomic tests revealed significant differences between 
the PN and CS (Table 1, Fig. 1). There were significant dif-
ferences between the two subject groups in SCOPA-AUT 
scores for all autonomic systems except for sexual disturbanc-
es. For the part of the questionnaire pertaining to sexual dis-
turbances, the SCOPA-AUT scores for the male and female 
PN were 0.60±1.10 and 1.60±1.67, respectively, while those 
for their CS counterparts were both 0.00±0.00. The total PD-
NMS score was 10.53±4.78 for PN and 1.80±2.31 for CS. 
Narcolepsy: a Multisystem Disorder?
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Autonomic dysfunction was significantly more common in 
PN than in CS.
Sensory testing
Both the PN and CS exhibited hyposmia, as defined by the 
UPSIT test. The score did not differ significantly between PN 
(31.33±5.27) and CS (33.47±2.75, p=0.18). However, the 
distribution of the severity of hyposmia differed between the 
two groups, there being more markedly affected subjects 
among the PN than the CS (data not shown). Color discrimi-
nation was not different in the two groups, with FM-100 
scores of 59.50±35.44 and 50.87±39.80 for PN and CS, re-
spectively.
Further evaluations
Depression was present in all of the PN but none of the CS. A 
high frequency of RBD was found for PN (87%), while RBD 
was totally absent in CS, as evidenced by the RBD-SQ.
Discussion
The findings of this study demonstrate that patients with nar-
colepsy also suffer from clinically relevant dysautonomia. 
The affected autonomic domains include pupillomotor func-
tion, the urinary, gastrointestinal, and cardiovascular systems, 
and thermoregulation. The SCOPA-AUT questionnaire, which 
was designed to assess nonmotor symptoms in IPD, provides 
the most concise evidence for these disturbances, while the 
pathological score on the PDNMS, which also assesses various 
sleep disturbances, is at least in part attributable to the intrin-
sic sleep dysfunction of NP. Neither of these instruments has 
yet been used in the assessment of PN. Both have been inde-
pendently validated and are commonly recommended as screen-
ing tools for IPD patients (e.g., by the Movement Disorder 
Task Force on Rating Scales).6 The SCOPA-AUT question-
naire exhibits neither floor nor ceiling effects. Although not 
comparatively tested in this study, IPD patients typically achieve 
mean scores in both tests that are similar to those achieved 
by the PN in the present study.7 In both of these disease groups 
(i.e., patients with IPD and PN), urinary dysfunction scores are 
the highest, followed by those for gastrointestinal dysfunction 
in IPD patients and those for thermoregulation in PN.
Narcolepsy is commonly considered to be due to deficient 
Table 1. Dysautonomia in narcolepsy 
Patients with  
narcolepsy (n=15)
Control subjects 
(n=15)
p-value
SCOPA-AUT (total) 18.47±10.08 4.40±3.09 <0.01
Cardiovascular 1.93±1.98 0.40±0.51 0.06
Gastrointestinal 3.80±2.98 1.20±1.32 0.04
Pupillomotor 0.80±0.94 0.13±0.35 0.10
Sexual (f) 1.60±1.67 0 0.24
Sexual (m) 0.60±1.10 0 0.24
Thermoregulatory 4.47±2.47 0.93±1.16 <0.01
Urinary 6.60±4.87 1.73±1.71 <0.01
PDNMS 10.53±4.78 1.80±2.31 0.02
UPSIT score 31.33±5.27 33.47±2.75 0.36
FM-100 (total) 59.50±35.44* 50.87±39.80 0.38
RBD-SQ 7.27±3.10 1.40±1.40 <0.01
BDI 8.93±7.18 2.00±2.51 0.02
Data were presented as mean±SD values. 
BDI: Beck Depression Inventory, f: female, FM-100: Farnsworth-
Munsell 100 hue-test, m: male, n: number of subjects, PDNMS: 
Parkinson’s Disease Nonmotor Symptoms, RBD-SQ: REM sleep 
behaviour disorder screening questionnaire, SCOPA-AUT: 
Scales for Outcomes in Parkinson-Autonomic, UPSIT: University 
of Pennsylvania Smell Identification Test.
Fig. 1. Results of the PDNMS questionnaire in 15 patients with narcolepsy and 15 control subjects. apath: apathy, cardio: cardiovascular 
system, depre: depression, gastro: gastrointestinal system, hallu: hallucinations, misc: miscellaneous, PDNMS: Parkinsonʼs Disease Non-
motor Symptoms, sex: sexual system, sleep: sleep disturbances, urin: urinary system.
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hypocretin transmission, although reduced hypocretin levels 
in the CSF have routinely been evidenced only in PN with 
cataplexy. However, it is improbable that the pathophysiolog-
ical cascade would be completely different in PN without cat-
aplexy. CSF hypocretin levels were not assessed in the pres-
ent cohort; we consider this to be a limitation of our study. 
We are also well aware that some dysautonomic complaints 
may be due to side effects of the medication. Despite these 
restrictions, we have (hypothetically) retained the concept 
that dysautonomia in narcolepsy may result from hypocretin 
deficiency. Below we briefly discuss both the pathophysio-
logical and neuroanatomical data supporting this hypothesis. 
Early speculation regarding a putative connection between 
narcolepsy and dysautonomia were formulated without the 
knowledge of the hypocretin system. Nowadays there is more 
evidence of an association between narcolepsy and dysauto-
nomia, although as recently pointed out, most studies are 
hampered by a lack of standardization or replication.8
Pupillomotor dysfunction 
The preganglionic neurons of the ciliary ganglion in the orbit 
are stimulated by hypocretin-containing nerve fibers. Via this 
pathway, emotional excitation and level of vigilance influence 
both the pupillary reaction to light and diurnal variations of the 
pupillary diameter.9 Reduced levels of hypocretin in narcolep-
sy could thus induce disturbances of the pupillomotor function 
and trigger increased sensitivity to light or, indirectly, disturbed 
vision. We therefore cannot exclude the possibility that the 
somnolence per se also impairs pupillomotor function in PN.
Gastrointestinal dysfunction 
The findings of the present study show that PN often complain 
about constipation and premature satiation. Gastrointestinal dis-
turbances have not been described in PN. The lateral hypothal-
amus, which contains hypocretin-producing neurons, is known 
to play a role in the acid secretion of the stomach, being partic-
ularly active during hunger periods. It stimulates acid secretion 
particularly during the cephalic phase, influenced by sensory 
stimuli. Furthermore, the vagal system is probably also con-
trolled in part by the hypocretin system. Intraventricular ap-
plication of hypocretin-1 in rats induces a dose-dependent in-
crease in gastric acid secretion, an effect that is abolished by 
vagotomy or administration of atropine.10 Anatomically, the 
lateral hypothalamus is connected to the vagal system by the 
dorsal vagal complex and the dorsal motor nucleus (DMN). 
In rats, injection of hypocretin-1 in the DMN induces stom-
ach contractions followed by stomach emptying.11
Cardiovascular dysfunction
In the present cohort, PN frequently complained of orthostat-
ic symptoms. It is known that PN exhibit attenuation of car-
diovascular reflexes in comparison to healthy controls: during 
isometric muscular exercise, the increase in heart frequency 
in PN is reduced when compared to healthy controls. Respi-
ratory sinus arrhythmia and heart rate are reduced during the 
Valsalva maneuver, and orthostatic counter-regulation is blunt-
ed after prolonged standing in PN.12 Finally, after arousals 
during REM and non-REM sleep, PN react with a reduced 
sympathetically driven heart rate increase in comparison to 
controls.13 In the rat, intraventricular application of hypocre-
tin-1 increases blood pressure and serum levels of norepineph-
rine.14 Efferent hypocretinergic pathways target the rostral 
ventrolateral medulla (RVLM) and the intermediolateral spi-
nal cord.15 Neurons of the RVLM control cardiovascular re-
flexes and sympathetic activity.16
Thermoregulation
Our NP also reported increased transpiration. Consistent 
with this, an increased distal-extremity diurnal body temper-
ature has been observed in PN.17 In healthy subjects this can 
be observed at nighttime, with increased external temperatures 
or after prolonged standing. Artificially induced increases in 
body temperature are followed by impaired vigilance (som-
nolence) in PN.18 It is conceivable that increased body tem-
perature may also contribute to daytime sleepiness in PN. The 
ventromedial medullary raphe nucleus (VMMR) contains 
presympathetic neurons for thermoregulation, which project 
to the lateral hypothalamus. Although there is no direct proof 
for the existence of hypocretin-containing neurons in the 
VMMR, it is well established that the lateral hypothalamus 
influences thermoregulation via regulation of the VMMR. 
This influence is most likely mediated via hypocretin-con-
taining fibers.
Urinary dysfunction
The present data suggest that NP suffer from an increased fre-
quency of urination during daytime or nighttime. In healthy 
subjects, urine production increases with acute sleep depriva-
tion but slows down during sleep. It is thus conceivable that 
disturbed sleep at nighttime, as frequently observed in narco-
lepsy, induces increased urine production.
Sexual dysfunction
No significant differences between the two groups were found 
for libido and sexual function, although PN complained 
more often about sexual disturbances than CS. In a large co-
hort study, 21% of 347 NP indicated such dysfunction.19 
These symptoms had only developed 10–20 years after dis-
ease onset. It is thus possible that the middle-aged PN of this 
cohort, who had suffered from narcolepsy for 14.2±6.2 
Narcolepsy: a Multisystem Disorder?
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years, may exhibit these symptoms at a later stage of their 
disease. Furthermore, a larger cohort might have revealed 
significant differences in this regard between the two groups.
Other evaluations
Findings other than those regarding autonomic dysfunction in 
our NP need to be discussed. Depression has been reported fre-
quently in PN.20 Reactive depression (to the disease) needs to 
be differentiated from a disease-inherent depression. Hypocre-
tin modulates the circuitries involved in reward and stress man-
agement, and hypocretin-1 and -2 ionic channels influence 
5-HT (serotonin)-producing neurons.21,22 Likewise, hyposmia 
is a well-recognized feature of narcolepsy.23 Hypocretin-con-
taining nerve fibers diffusively innervate the olfactory net-
work. Surprisingly, in our cohort hyposmia was present in 
both PN and CS. It is possible that the UPSIT test, which 
was primarily developed for American subjects, contains smell 
probes that are less familiar to European subjects (e.g., root 
beer and cheddar cheese) and thus not sufficiently discrimi-
nated by our cohort. The relatively high prevalence of hypos-
mia in our PN (60%) could be attributable to the small cohort; 
prevalence rates of 35–40% have been found in larger stud-
ies.23 Finally, smoker status may have been a substantial con-
founding factor, masking more subtle disease-inherent hypos-
mia in PN, although no significant differences were observed 
between the two groups. It is notable that none of our pa-
tients had a complete anosmia and none had noted the hy-
posmia previously. RBD is considered to be primarily due to 
hypocretin deficiency, possibly in the sublaterodorsal tegmen-
tal nucleus, one of the brainstem nuclei that regulates REM 
sleep. RBD prevalence among PN is increased in comparison 
to the general population.24 We found both a high and gen-
der-neutral occurrence of RBD in our cohort using the RBD-
SQ, which to the best of our knowledge has not yet been used 
in the assessment of PN. However, polysomnography did not 
confirm the diagnosis in this cohort. The high prevalence of 
RBD observed in our cohort of PN could also be due in part to 
their medical treatment. RBD occurs early in PN, and the mean 
age of our cohort was 35 years.24 In contrast, RBD is mostly a 
late-adult-life syndrome in patients with α-synucleinopathy, 
although it can precede the core Parkinsonian syndrome by 
decades.25
Finally, PN exhibit normal visual performance, and score 
similarly to CS in terms of color discrimination and contrast 
sensitivity. We believe that this finding is remarkable since it 
is the only one that distinguishes PN from patients with idio-
pathic RBD or patients with α-synucleinopathy in terms of 
“silent comorbidity,” namely sensory deficits, depression, 
RBD, and in particular, dysautonomic signs. Thus, patients 
with idiopathic RBD-a possible precursor syndrome of IPD-
and IPD patients, at an early stage of the disease, already suf-
fer from EDS in addition to showing dysautonomic signs, hy-
posmia, RBD, and depression.4 Moreover, IPD patients exhibit 
significant disturbances of color and contrast discrimination, a 
finding that is absent in PN.4 Despite this notable discrepan-
cy, we hypothesize that the complex syndrome identified in 
PN offers striking similarities with the multisystem involve-
ment observed in IPD. The present data strongly suggest that 
beyond the classical tetrad of narcolepsy, patients with this 
disorder suffer from dysautonomic, depressive, and olfactory 
symptoms. It should be emphasized that such symptoms are 
often not declared by IPD patients to health professionals, al-
though they strongly correlate with quality of life;26 the same 
may be true for PN.
Together the above-mentioned findings suggest that narco-
lepsy, although possibly triggered by an autoimmune pro-
cess, nevertheless evolves into another progressive multisys-
tem disease, a concept that is easily compatible with the diffuse 
connectivity of the hypocretin system, especially in the brain-
stem. Step-by-step progressive multisystem involvement in 
IPD has been suggested by Braak et al.27 However, there is a 
dearth of clinical data on the temporal evolution of dysauto-
nomic and sensory deficits in narcolepsy, as well as postmor-
tem studies to confirm or refute such a hypothesis.28
In addition to the symptom parallelism between IPD and 
narcolepsy, a direct pathochemical link has also been proposed 
based on pilot findings on decreased tissue levels of hypocre-
tin and corresponding decreased numbers of hypocretin-con-
taining neurons in IPD patients.29 However, the data remain 
controversial. Nevertheless, hypocretin deficiency has also been 
proposed in IPD to explain why some IPD patients exhibit 
EDS, even ahead of the motor manifestations of the disease, 
and why other patients react with EDS to the treatment with 
D3-dopamine agonists.30 Finally, it has been suggested that 
narcolepsy predisposes the patient to IPD. In a cohort of 1,152 
PN, 3 later developed IPD, a rate that is 5 times higher than 
that in the general population. This raises the possibility that 
some factors intrinsic to narcolepsy or its treatment constitute 
risk factors for IPD.31
Some limitations of our study need to be mentioned. First, 
the sample was small and so the results must be replicated in 
larger cohorts. However, the results concerning the primary 
outcome variables remained robust after adjustment for multi-
ple comparisons. The sample was too small to compare PN 
with and without cataplexy, and the CSF levels of hypocre-
tin-1 were not determined. While alluding to similar deficits in 
IPD patients, a direct comparison with IPD patients was not 
performed, since an age effect would have confounded such 
an investigation. We did not perform objective autonomic tests 
to confirm the dysautonomia complaints assessed by the ques-
Klein G et al.
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tionnaires. Finally, we were unable to evaluate patients who 
were not taking medication. Stimulants can modulate the au-
tonomous nervous system, but acute withdrawal can also have 
a significant impact.32 Despite these limitations, we are confi-
dent that the findings of this exploratory study can be used to 
generate testable hypotheses, eventually anchoring narcolepsy 
within the spectrum of diseases with a multisystem impact.
In conclusion, The present data strongly suggest that be-
yond the classical tetrad of narcolepsy, patients with this dis-
order suffer from dysautonomic symptoms and confirm the 
comorbidities depression and RBD. The spectrum is compa-
rable to the non-motor complex in IPD.
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